Therapeutic Goals in the Treatment of Gaucher Disease

  • Neal Weinreb


Enzyme Replacement Therapy Gauche Disease Therapeutic Goal Spleen Volume Hepatopulmonary Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aghion E (1934). La maladie de Gaucher dans l’enfance. These, Faculte de Medicine, Paris.Google Scholar
  2. Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, et al. (2000). Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis 26: 285-290.CrossRefPubMedGoogle Scholar
  3. American Diabetes Association (2005). Standards of medical care in diabetes. Diabetes Care; 28 S1: 540-536.Google Scholar
  4. Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakesh-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ. For the International Collabo-rative Gaucher Group U.S. Regional Coordinators (2005). Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 7: 105-110.Google Scholar
  5. Barton NW, Brady RO, Dambrosia JM et al. (1991). Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Eng J Med 324: 1464-1470.CrossRefGoogle Scholar
  6. Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ (2002). Bone complications in children with Gaucher disease. Br J Radiol 75 suppl 1: A37-A43.Google Scholar
  7. Beutler E, Grabowski GA (2001). Gaucher disease. In Scriver CR, Beaudet AC, Sly WS, Valle D, Eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill, pp. 3635-3668.Google Scholar
  8. Beutler E, Kuhl W (1970). The diagnosis of the adult type of Gaucher’s disease and its carrier state by demonstration of a deficiency of beta-glucosidase avtivity in peripheral blood leukocytes. J Lab Clin Med 76: 747-755.PubMedGoogle Scholar
  9. Bijsterbosch MK, Donker W, van de Bilt H, van Weely S, van Berkel TJ, Aerts JM (1996). Quantitative analysis of the targeting of mannose-terminal glucoderebrosidase. Predominant uptake by liver endothelial cells. Eur J Biochem 237: 344-349.CrossRefPubMedGoogle Scholar
  10. Boot RG, Verhoek M, De Fost M, Hollak CE, Maas M, Bleijlevens B, et al. (2003). Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood 103: 33-39.CrossRefPubMedGoogle Scholar
  11. Brady RO, Kanfer J, Shapiro D (1965). Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem Biophys Res Comm 18: 221-225.CrossRefPubMedGoogle Scholar
  12. Cabrera-Salazar MA, O’Rourke E, Henderson N, Wessel H, Barranger JA (2004). Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clin Chim Acta 344: 101-107.CrossRefPubMedGoogle Scholar
  13. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. (2000). The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160: 2835-2843.CrossRefPubMedGoogle Scholar
  14. Charrow J, Esplin JA, Gribble TJ, Kaplan P, Kolodny EH, Pastores GM, et al. (1998). Gaucher disease: Recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 158: 1754-1760.CrossRefPubMedGoogle Scholar
  15. Ciana G, Addobbati R, Tamaro G, Leopaldi A, Nevyjel M, Ronfani L, Vidoni L, Pittis MG, Bembi B (2005). Gaucher disease and bone: Laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 28: 723-732.CrossRefPubMedGoogle Scholar
  16. Czartoryska B, Tylki-Szymanska A, Lugowska A (2000). Changes in serum chitotrio-sidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem 33: 147-149.CrossRefPubMedGoogle Scholar
  17. Damiano AM, Pastores GM, Ware JE (1998). The health-related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: Results from a retrospective study. Qual Life Res 7: 373-386.CrossRefPubMedGoogle Scholar
  18. Dawson A, Elias DJ, Rubenson D, Bartz SH, Garver PR, Kay AC, et al. (1996). Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann Intern Med 125: 901-904.PubMedGoogle Scholar
  19. Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JM, Cox TM (2005). Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cels Mol Dis 35: 259-267.CrossRefGoogle Scholar
  20. Dvir H, Harel M, McCarthy AA, Toker L, Silman I, Futerman AH, Sussman JL (2003). X-ray structure of human acid-betga-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep 4: 704-709.CrossRefPubMedGoogle Scholar
  21. Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A (2000). Withdrawal of enzyme replacement therapy in Gaucher’s disease. Br J Haematol 110: 488-492.CrossRefPubMedGoogle Scholar
  22. Elstein D, Klutstein MW, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A (1998). Echocardiographic assessment of pulmonary hypertension in Gaucher’s disease. Lancet 351: 1544-1546.CrossRefPubMedGoogle Scholar
  23. Furbish FS, Blair HE, Shiloach J et al. (1984). Interaction of human placental glucocere-brosidaes with hepatic lectins. In Barranger JA & Brady RO, Eds. Molecular Basis of Lysosomal Storage Disorders. Orlando, FL: Academic Press, pp. 219-232.Google Scholar
  24. Gaucher Registry (2004). Available at: Gilbert HS, Weinreb NJ (1976). Increased circulatory levels of transcobalamin II in Gaucher’s disease. New Eng J Med 295: 1096-1101.Google Scholar
  25. Gillis S, Hyam E, Abrahamov A, Elstein D, Zimran A (1999). Platelet function Abnor-malities in Gaucher disease patients. Am J Hematol 61: 103-106.CrossRefPubMedGoogle Scholar
  26. Ginns EI, Choudary PV, Tsiji S, et al. (1984). Isolation of cDNA clones for human β-glucocerebrosidase using the λgt11 expression system. Biochem Biophys Res Comm 123: 574-580.CrossRefPubMedGoogle Scholar
  27. Giraldo P, Cenarro A, Alfonso P, Perez-Calvo JI, Rubio-Felix D, Giralt M, et al. (2001). Chitotriosidase genotype and plasma activity in patients type 1 Gaucher’s disease and their relatives (carriers and non carriers). Haematologica 86: 977-984.PubMedGoogle Scholar
  28. Giraldo P, Solano V, Perez-Calvo JI, Giralt M, Rubio-Felix D, Spanish Group of Gaucher Disease (2005). Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 14: 453-462.Google Scholar
  29. Goker-Alpan O, Hruska KS, Orvisky E, Kishnani PS, Stubblefield BK, Schiffmann R, Sidransky E (2005). Divergent phenoypes in Gaucher diseae implicate the roe of modifiers. J Med Genet 42: e37.CrossRefPubMedGoogle Scholar
  30. Grabowski GA (2005). Recent clinical progress in Gaucher disease. Curr Opin Pediatr 17: 519-524.CrossRefPubMedGoogle Scholar
  31. Grabowski GA, Hopkin RJ (2003). Enzyme therapy for lysosomal storage disease: Principles, practice, and prospects. Annu Rev Genomics Hum Genet 4: 403-436.CrossRefPubMedGoogle Scholar
  32. Grinzaid KA, Geller E, Hanna SL, Elsas LJ 2nd (2002). Cessation of enzyme replace-ment therapy in Gaucher disease. Genet Med 4: 427-433.PubMedCrossRefGoogle Scholar
  33. Harats D, Pauzner R, Elstein D, Many A, Klutstein MW, Kramer MR, et al. (1997). Pulmonary hypertension in two patients with type I Gaucher disease while on alglucerase therapy. Acta Haematol 98: 47-50.CrossRefPubMedGoogle Scholar
  34. Hillborg PO (1959). Morbus Gaucher: Norbotten. Nordisk Medicin. 61: 303-306.PubMedGoogle Scholar
  35. Ho MW, Seck J, Schmidt D, Veath ML, Johnson W, Brady RO, O’Brien JS (1972). Adult Gaucher’s disease: Kindred studies and demonstration of a deficiency of acid-glucosidase in cultured fibroblasts. Am J Hum Genet 24: 37-45.PubMedGoogle Scholar
  36. Hollak C, Maas M, Akkerman EM, den Heeten GJ, Aerts H (2001a). Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualised doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 27: 1005-1012.CrossRefGoogle Scholar
  37. Hollak CE, Maas M, Aerts JM (2001b) Clinically relevant therapeutic endpoints in type I Gaucher disease. J Inherit Metab Dis 24 suppl 2: 9097-9105.CrossRefGoogle Scholar
  38. Hollak CE, van Weely S, van Oers MH, Aerts JM (1994). Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93: 1288-1292.CrossRefPubMedGoogle Scholar
  39. Ida H, Rennert OM, Kobayashi M, Eto Y (2001). Effects of enzyme replacement therapy in thirteen Japanese paediatric patients with Gaucher disease. Eur J Pediatr 160: 21-25.CrossRefPubMedGoogle Scholar
  40. Kaplan P, Mazur A, Manor O, Charrow J, Esplin J, Gribble TJ, et al. (1996). Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 129: 149-153.CrossRefPubMedGoogle Scholar
  41. Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, et al. (2000). Delayed growth and puberty in patients with Gaucher disease type 1: Natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2: 158-163.PubMedGoogle Scholar
  42. Korolenko TA, Zhanaeva SY, Falameeva OV, Kaledin VI, Filyushina EE, Buzueva II, et al. (2000). Chitotriosidase as a marker of macrophage stimulation. Bull Exp Biol Med 130: 948-950.PubMedGoogle Scholar
  43. Lachmann RH, Grant IR, Halsall D, Cox TM (2004): Twin pairs showing discordance of phenotype in adult Gaucher’s disease. Q J Med 97: 199-204.Google Scholar
  44. Lee RE (1982). The pathology of Gaucher disease, In Desnick RJ, Gatt S, Grabowski GA, Eds. Gaucher Disease: A Century of Delineation and Research. New York: Liss, pp. 177-217.Google Scholar
  45. Maas M, van Kuijk C, Stoker J, Hollak CE, Akkerman EM, Aerts JF, et al. (2003). Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging— Initial experience. Radiology 229: 554-561.CrossRefPubMedGoogle Scholar
  46. Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, Prins M, Aerts H, Poll R (2000). The natural course of Gaucher disease in The Netherlands: Implications for monitoring of disease manifestations. J Inherit Metab Dis 23: 77-82.CrossRefPubMedGoogle Scholar
  47. Mistry PK, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, et al. (2002). Pulmonary hypertension in type 1 Gaucher’s disease: Genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 77: 91-98.CrossRefPubMedGoogle Scholar
  48. Morgan MA, Hoffbrand AV, Laulicht M, Luck W, Knowles S (1983). Serum feritin concentration in Gaucher’s disease. Br Med J 286: 1864.CrossRefGoogle Scholar
  49. Mota R (2004). Bone disease as a parameter of evaluation of therapy, progression, and effectiveness in Gaucher disease. Paper presented at the Latin American Symposium for Lysosomal Storage Diseases. Santiago, Chile, August 7-8, 2004.Google Scholar
  50. NIH Technology Assessment Panel on Gaucher Disease (1996). Gaucher disease: Current issues in diagnosis and treatment. JAMA. 275: 548-553.CrossRefGoogle Scholar
  51. Oberling C, Woringer P (1927). La maladie de Gaucher chez la nourisson. Revue Francais de Pediatrie. 3: 475-532.Google Scholar
  52. Pastores GM, Sibille AR, Grabowski GA (1993). Enzyme therapy in Gaucher disease type 1: Dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 82: 408-416.PubMedGoogle Scholar
  53. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymanska A (2004). Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41(4 Suppl 5): 4-14.CrossRefPubMedGoogle Scholar
  54. Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, et al. (2001). Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: First German long-term results. Skeletal Radiol 30: 496-503.CrossRefPubMedGoogle Scholar
  55. Poll LW, Maas M, Terk MR, Roca-Espiau M, Bembi B, Ciana G, et al. (2002). Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 75 suppl 1: A25-A36.PubMedGoogle Scholar
  56. Premkumar L, Sawkar AR, Boldin-Adamsky S, Toker L, Silman I, Kelly, JW, Futerman AH, Sussman JL (2005). X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease. J Biol Chem 280: 23815-23819.CrossRefPubMedGoogle Scholar
  57. Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, et al. (1995). Enzyme replacement therapy for Gaucher disease: Skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96: 629-637.PubMedGoogle Scholar
  58. Sato Y, Beutler E (1993). Binding, internalization, and degradation of mannose-termi-nated glucocerebrosidase by macrophages. J Clin Invest 91: 1909-1917.CrossRefPubMedGoogle Scholar
  59. Schwartz IV, Karam S, Ashton-Prolla P, Michelin K, Coelho J, Pires RF, et al. (2001). Effects of imiglucerase withdrawal on an adult with Gaucher disease. Br J Haematol 113: 1089.CrossRefPubMedGoogle Scholar
  60. Silverstein E, Friedland J (1977). Elevated serum and spleen angiotensin converting enzyme and serum lysozyme in Gaucher’s disease. Clin Chim Acta 74: 21-25.CrossRefPubMedGoogle Scholar
  61. Sirrs S, Irving J, McCauley G, Gin K, Munt B, Pastores G, et al. (2002). Failure of resting echocardiography and cardiac catheterization to identify pulmonary hypertension in two patients with type I Gaucher disease. J Inherit Metab Dis 25: 131-132.CrossRefPubMedGoogle Scholar
  62. Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K, et al. (2003). Gaucher disease with Parkinsonian manifestations: Does glucocerebrosidase defi-ciency contribute to a vulnerability to Parkinsonism? Mol Genet Metab 79: 104-109.CrossRefPubMedGoogle Scholar
  63. Terk MR, Dardashti S, Liebman HA (2000). Bone marrow response in treated patients with Gaucher disease: Evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. Skeletal Radiol 29: 563-571.CrossRefPubMedGoogle Scholar
  64. Toth J, Erdos M, Marodi L (2003). Rebound hepatosplenomegaly in type 1 Gaucher disease. Eur J Haematol 70: 125-128.CrossRefPubMedGoogle Scholar
  65. Vellodi A, Bembi B, de Villemeur TB, Collin-Histed T, Erikson A, Mengel E, et al. (2001). Management of neuronopathic Gaucher disease: A European consensus. J Inherit Metab Dis 24: 319-327.CrossRefPubMedGoogle Scholar
  66. vom Dahl S, Poll LW, Haussinger D (2001). Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br J Haematol 113: 1084-1087.CrossRefGoogle Scholar
  67. Ware JE (1993) SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center.Google Scholar
  68. Weinreb NJ (2001). Interruption in enzyme replacement therapy for Gaucher disease. Br J Haematol 113: 1087-1089.CrossRefPubMedGoogle Scholar
  69. Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JTR, Erikson A, Giraldo, Goldblatt J, Hollak C MD, Ida H, Kaplan P, Kolodny EH, Mistry P, Pastores GM, Pires R, Prakesh-Cheng A, Rosenbloom BE, Scott CR, Sobreira E, Tylki-Szymanska A, Vellodi A, vom Dahl S, Wappner RS, Zimran A (2004). Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients. Seminars in Hematology; 41 S5: 15-22.CrossRefPubMedGoogle Scholar
  70. Weinreb NJ, Charrow J, Andersson HC, et al. (2002). Effectiveness of enzyme replace-ment therapy in 1,028 patients with type 1 Gaucher disease after 2-5 years of treat-ment: A report from the Gaucher Registry. Am J Med. 113: 112-119.CrossRefPubMedGoogle Scholar
  71. Wenstrup RJ, Bailey L, Grabowski GA, Moskovitz J, Oestreich AE, Wu W, Sun S (2004). Gaucher disease: Alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood; 104: 1253-1257.CrossRefPubMedGoogle Scholar
  72. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B (2002). Skeletal aspects of Gaucher disease: A review. Br J Radiol 75 Suppl 1: A2-A12.Google Scholar
  73. Whitfield PD, Nelson P, Sharp PC, Bindloss CA, Dean C, Ravenscroft EM, et al. (2002). Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: Implications for the prediction of disease severity. Mol Genet Metab 75: 46-55.CrossRefPubMedGoogle Scholar
  74. Young E, Chatterton C, Vellodi A, Winchester B (1997). Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplan-tation or by enzyme replacement therapy with alglucerase. J Inherit Metab Dis 20: 595-602.CrossRefPubMedGoogle Scholar
  75. Zevin S, Abrahamov A, Hadas-Halpern I, Kannai R, Levy-Lahad E, Horowitz M, et al. (1993). Adult-type Gaucher disease in children: Genetics, clinical features and enzyme replacement therapy. Q J Med 86: 565-573.PubMedGoogle Scholar
  76. Zhao H, Bailey LA, Grabowski GA (2003). Enzyme therapy of Gaucher disease: Clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol Dis 30: 90-96.CrossRefPubMedGoogle Scholar
  77. Zhu Y, Li X, Schuchman EH, Desnick RJ, Cheng SH (2004). Dexamethasone-mediated up-regulation of the mannose receptor improves the delivery of recombinant glucocere-brosidase to Gaucher macrophages. J Pharmacol Exp Ther 308: 705-711.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Neal Weinreb
    • 1
  1. 1.University Research Foundation for Lysosomal Storage DiseasesNorthwest Oncology Hematology Associates PACoral SpringsUSA

Personalised recommendations